Cochrane Review Links Drug-Company Promotion to Less Appropriate, Costlier Prescribing
An updated systematic review of 93 studies finds that gifts, paid meals and marketing to clinicians are associated with worse prescribing, while strong conflict-of-interest policies appear to help.
Review of 93 studies links pharma gifts, meals and marketing to less appropriate, more frequent and costlier prescribing.
written by Vital Biomedical News Staff
Pharmaceutical companies reach the clinicians who prescribe their products through sales-representative visits, sponsored education, paid meals, travel, consulting fees and free samples. Whether those interactions change prescribing has long been debated, and many clinicians believe they are not personally swayed.
In releases dated October 8 and 9, 2026, York University and Cochrane announced an updated systematic review in the Cochrane Database of Systematic Reviews titled "Pharmaceutical industry information and promotional strategies aimed at prescribers" [1][3]. The lead author is Barbara Mintzes of the University of Sydney; co-authors named in the accompanying releases include Lisa Bero of the University of Colorado Anschutz and Joel Lexchin, professor emeritus at York University [2][3].
What Was Found
The review included 93 studies [2][3]. The authors grouped industry activities into three categories: advertising and education (such as sales-rep visits), gifts and payments (such as meals, travel and consulting fees), and free drug samples. They also assessed conflict-of-interest policies as a counter-measure [2].
Gifts and payments had the largest and most consistent evidence base, drawing on data covering millions of prescribers [2][4]. About two-thirds of the included studies assessed payments, gifts or other transfers of value [4]. These were associated with less appropriate prescribing and more prescriptions, and probably with higher costs [2][4][5].
Paid meals showed a dose–response pattern: the more company-paid meals a physician received, the more that company's drug they prescribed. Cochrane reports this held across drugs for high blood pressure, cholesterol, depression and pain (opioids) [2]. Fierce Pharma reports the pattern was seen across seven drug classes [4].
Opioids: even low-cost meals were associated with more opioid prescribing, and more payments from opioid makers were associated with a higher likelihood of dangerously high opioid doses [2].
Advertising and education probably increase the number of prescriptions and may increase inappropriate prescribing and costs, according to trade-press summaries of the review's certainty ratings [4][5]. The underlying datasets ranged from under 1,000 to more than 150,000 physicians, depending on the question [4].
Free samples: evidence (7 studies) was too uncertain for firm conclusions [4]. Evidence on hospital formulary decisions was also too sparse [2][5].
Conflict-of-interest policies (8 studies) probably improve the appropriateness of prescribing and may reduce prescription volume; their effect on costs is uncertain [2][4].
Mintzes said many doctors believe they "can't be bought for the price of a sandwich," a view she said the data contradict [4]. Lexchin said the review "puts to rest the myth" that prescribers benefit from exposure to company promotion [3].
Study Design and Limitations
This is a systematic review, not a new trial. Almost all of the included studies were observational analyses of real-world prescribing rather than controlled experiments [2][3], so they show associations and cannot by themselves prove that promotion causes prescribing changes. Doctors who accept more industry contact may differ in other ways from those who do not.
The evidence is also heavily American: 88% of the studies came from the United States [2][3]. Cochrane notes that the 2010 Physician Payments Sunshine Act, which requires public reporting of industry payments to doctors, made much of this research possible [2]. How well the findings apply to countries with different rules is not established.
The press materials and coverage reviewed for this article did not report the review's funding sources or the authors' declarations of interest, and pooled effect sizes could not be verified for this report. Readers should consult the full review for those details [1].
Clinical and Patient Implications
The review's central message is that the issue is systemic rather than confined to a few individuals. Bero described the practices as "business-as-usual" within the industry [2]. For patients, the concern is that treatment choices may be shaped by marketing rather than by clinical evidence, with possible effects on safety, as the opioid findings suggest, and on cost [2].
The more hopeful finding concerns policy. Robust conflict-of-interest policies were associated with more appropriate prescribing [2][3]. The authors describe such policies as a way forward [2].
The coverage reviewed for this article did not include a response from pharmaceutical industry trade groups.
What Comes Next
Much of the evidence base exists because U.S. law requires industry payments to doctors to be publicly reported [2]. The authors argue that institutional policy, rather than individual willpower, is the practical lever [2]. Further controlled studies, and more data from outside the United States, would help clarify cause and effect.
This article is for informational purposes only and is not medical advice. Readers should consult their clinician about their own care.
References
Mintzes B (lead author) and colleagues. Pharmaceutical industry information and promotional strategies aimed at prescribers. Cochrane Database of Systematic Reviews. October 2026. DOI: 10.1002/14651858.CD013423.pub3. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013423.pub3
Parkinson M. Pharmaceutical company marketing negatively influences prescribing. Cochrane News. October 9, 2026. https://www.cochrane.org/about-us/news/pharmaceutical-company-marketing-negatively-influences-prescribing
York University. Pharmaceutical company marketing negatively influences prescribing. News@York. October 8, 2026. https://yorku.ca/news/2026/10/08/pharmaceutical-company-marketing-negatively-influences-prescribing
Taylor NP. Free lunches for clinicians bloat prescription bills: Cochrane review. Fierce Pharma. October 9, 2026. https://www.fiercepharma.com/marketing/pharmas-free-lunches-clinicians-bloat-prescription-bills-cochrane-review
STAT. Pharma's free lunches for doctors boost inappropriate prescribing, analysis finds. STAT (Pharmalot). October 9, 2026. https://www.statnews.com/pharmalot/2026/10/09/pharma-free-lunches-to-doctors-boost-inappropriate-prescribing/